| Hazard Information | Back Directory | [Uses]
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity[1][2]. | [in vivo]
Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. | Animal Model: | Mice harbouring OPM2 tumours[2] | | Dosage: | 4 mg/kg | | Administration: | IP, twice weekly for 4 doses | | Result: | Signifcantly improves survival compared to vehicle. |
| [References]
[1] Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. DOI:10.1016/S1470-2045(19)30788-0
[2] Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. DOI:10.1007/s40265-020-01404-x |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|